SG11201809154UA - Nanoliposomes for sustained delivery of tacrolimus for treatment of anterior segment eye diseases - Google Patents

Nanoliposomes for sustained delivery of tacrolimus for treatment of anterior segment eye diseases

Info

Publication number
SG11201809154UA
SG11201809154UA SG11201809154UA SG11201809154UA SG11201809154UA SG 11201809154U A SG11201809154U A SG 11201809154UA SG 11201809154U A SG11201809154U A SG 11201809154UA SG 11201809154U A SG11201809154U A SG 11201809154UA SG 11201809154U A SG11201809154U A SG 11201809154UA
Authority
SG
Singapore
Prior art keywords
singapore
nanyang
avenue
international
nanoliposomes
Prior art date
Application number
SG11201809154UA
Other languages
English (en)
Inventor
Subramanian Venkatraman
Jayaganesh V Natarajan
Yin Chiang Freddy Boey
Jodhbir Singh Mehta
Tina Tzee Ling Howden
Xu Wen Ng
Original Assignee
Univ Nanyang Tech
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nanyang Tech, Singapore Health Serv Pte Ltd filed Critical Univ Nanyang Tech
Publication of SG11201809154UA publication Critical patent/SG11201809154UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201809154UA 2016-04-19 2017-04-19 Nanoliposomes for sustained delivery of tacrolimus for treatment of anterior segment eye diseases SG11201809154UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201603094P 2016-04-19
PCT/SG2017/050216 WO2017184080A1 (en) 2016-04-19 2017-04-19 Nanoliposomes for sustained delivery of tacrolimus for treatment of anterior segment eye diseases

Publications (1)

Publication Number Publication Date
SG11201809154UA true SG11201809154UA (en) 2018-11-29

Family

ID=60116958

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202010303UA SG10202010303UA (en) 2016-04-19 2017-04-19 Nanoliposomes for sustained delivery of tacrolimus for treatment of anterior segment eye diseases
SG11201809154UA SG11201809154UA (en) 2016-04-19 2017-04-19 Nanoliposomes for sustained delivery of tacrolimus for treatment of anterior segment eye diseases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202010303UA SG10202010303UA (en) 2016-04-19 2017-04-19 Nanoliposomes for sustained delivery of tacrolimus for treatment of anterior segment eye diseases

Country Status (6)

Country Link
US (2) US11672784B2 (zh)
EP (1) EP3445334B1 (zh)
JP (1) JP7186093B2 (zh)
CN (1) CN109310634B (zh)
SG (2) SG10202010303UA (zh)
WO (1) WO2017184080A1 (zh)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817333A (en) * 1991-10-31 1998-10-06 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing a tricyclic compound
CA2364257A1 (en) 1999-03-11 2000-09-14 Fujisawa Pharmaceutical Co., Ltd. Liposome preparations
US6489335B2 (en) 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
CN1127955C (zh) * 2000-07-07 2003-11-19 中山医科大学中山眼科中心 一种眼前段及眼表免疫相关性疾病治疗药物
US20040224010A1 (en) * 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof
WO2006050327A2 (en) * 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
JPWO2008026781A1 (ja) * 2006-08-31 2010-01-21 直人 奥 逆標的化脂質小胞体
US9750812B2 (en) * 2008-09-27 2017-09-05 Jina Pharmaceuticals, Inc. Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
AU2009301141B2 (en) * 2008-10-07 2015-08-27 Bracco Suisse S.A. Targeting construct comprising anti-polymer antibody and liposomes or microvesicles binding to the same
EP2480208A1 (en) * 2009-09-23 2012-08-01 Indu Javeri Methods for the preparation of liposomes
WO2012021107A2 (en) * 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
CN103142468A (zh) * 2012-12-28 2013-06-12 中山大学 用于眼角膜移植的他克莫司眼用剂及其制备方法
AU2014340137B2 (en) * 2013-10-22 2020-02-13 Lipella Pharmaceuticals Inc. Delivery of agents using metastable liposomes

Also Published As

Publication number Publication date
EP3445334A1 (en) 2019-02-27
JP7186093B2 (ja) 2022-12-08
JP2019513807A (ja) 2019-05-30
SG10202010303UA (en) 2020-11-27
CN109310634A (zh) 2019-02-05
EP3445334A4 (en) 2019-12-25
WO2017184080A1 (en) 2017-10-26
US20230263780A1 (en) 2023-08-24
US20190117631A1 (en) 2019-04-25
US11672784B2 (en) 2023-06-13
CN109310634B (zh) 2022-05-31
EP3445334B1 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201900596XA (en) Cannabis composition
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201811209QA (en) Oral gastroretentive formulations and uses thereof
SG11201408261UA (en) Syringe
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201803915UA (en) Echinomycin formulation, method of making and method of use thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201806625WA (en) Non-invasive ocular drug delivery insert technology
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201906729RA (en) Topical cyclosporine-containing formulations and uses thereof
SG11201811580SA (en) Compositions, devices, and methods for the treatment of alcohol use disorder
SG11201901389XA (en) Combination therapy with glutaminase inhibitors
SG11201901249YA (en) Aza-indazole compounds for use in tendon and/or ligament injuries
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201810403VA (en) Drug-delivery nanoparticles and treatments for drug-resistant cancer
SG11201810618QA (en) Depot formulations
SG11201809788VA (en) Nanoliposomal irinotecan for use in treating small cell lung cancer